Feedback
Settings

Settings

Goto Application

280,456 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,046
1.WO/2025/255245COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
WO - 11.12.2025
Int.Class C07H 19/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
 Appl.No PCT/US2025/032287 Applicant ROME THERAPEUTICS, INC. Inventor CHOBANIAN, Harry R.
Compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase activity, and their use in the treatment of medical disorders, such as cancer, are disclosed herein.
2.WO/2025/255246COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
WO - 11.12.2025
Int.Class C07H 19/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
 Appl.No PCT/US2025/032288 Applicant ROME THERAPEUTICS, INC. Inventor CHOBANIAN, Harry R.
Compounds, pharmaceutical compositions, and their use for inhibiting LINE1 reverse transcriptase, and their use in the treatment of medical disorders, such as cancer, are disclosed herein.
3.WO/2025/252741NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
WO - 11.12.2025
Int.Class C07H 15/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
26Acyclic or carbocyclic radicals, substituted by hetero rings
 Appl.No PCT/EP2025/065355 Applicant GALECTO BIOTECH AB Inventor PETERSON, Kristoffer
The present invention relates to a high affinity galectin-3 inhibitor alpha-D-galactopyranose derivative of formula (I), a pharmaceutical salt or solvate thereof, for use in treatment of inflammation.
4.WO/2025/255411METHODS AND COMPOSITIONS FOR REDUCING DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
WO - 11.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/032557 Applicant IONIS PHARMACEUTICALS, INC. Inventor BHANOT, Sanjay
Provided herein are methods of treating, preventing, or ameliorating a liver disease comprising administering a composition comprising about 75 mg to about 175 mg of an oligomeric compound comprising a modified antisense oligonucleotide inhibitor of diacylglycerol acyltransferase 2 (DGAT2). Additionally provided are unit doses and dosing regimens useful in the methods for treating, preventing, or ameliorating a liver disease, including MASLD and MASH, and complications thereof.
5.20250376496MICRO-DYSTROPHINS AND RELATED METHODS OF USE
US - 11.12.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No 19307571 Applicant UNIVERSITY OF WASHINGTON Inventor Jeffrey S. CHAMBERLAIN

Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.

6.20250376487LIPID-MODIFIED NUCLEIC ACID COMPOUNDS AND METHODS
US - 11.12.2025
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
 Appl.No 19220791 Applicant Novartis AG Inventor Arthur Suckow

Disclosed herein, inter alia, are lipid-modified nucleic acid compounds, their preparation, and their use.

7.20250374931METHOD OF REMOVING CALCIUM CITRATE FROM A LIQUID DAIRY STREAM
US - 11.12.2025
Int.Class A23C 9/142
AHUMAN NECESSITIES
23FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; PREPARATION, TREATMENT OR PRESERVATION THEREOF
CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
9Milk preparations; Milk powder or milk powder preparations
14in which the chemical composition of the milk is modified by non-chemical treatment
142by dialysis, reverse osmosis or ultrafiltration
 Appl.No 18877535 Applicant Arla Foods amba Inventor Kenneth Dyrmose Nielsen

The present invention relates to a method of removing calcium citrate from a liquid dairy stream. In particular, the present invention relates to a method of removing calcium citrate from a liquid dairy stream wherein the liquid dairy stream has a pH below 6.2 or is optionally adjusted to be below 6.2, and wherein said liquid dairy stream having a pH below 6.2 is subjected to a step of precipitation of calcium citrate. Subsequently, the precipitated calcium citrate can be separated.

8.WO/2025/2521525'-MODIFIED NUCLEOSIDE DERIVATIVE AND OLIGONUCLEOTIDE COMPRISING SAME
WO - 11.12.2025
Int.Class C07H 19/167
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
167with ribosyl as the saccharide radical
 Appl.No PCT/CN2025/099285 Applicant TUOJIE BIOTECH (SHANGHAI) CO., LTD. Inventor LIU, Haomiao
The present disclosure relates to a 5'-modified nucleoside derivative and an oligonucleotide comprising same. Specifically, the oligonucleotide comprises at least one structure represented by formula (I), wherein each functional group is defined in the context of the present disclosure.
9.WO/2025/252112DISACCHARIDE COMPOUND, ANTIBODY-DRUG CONJUGATE CONTAINING DISACCHARIDE COMPOUND, AND USE THEREOF
WO - 11.12.2025
Int.Class C07H 15/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
04attached to an oxygen atom of a saccharide radical
08Polyoxyalkylene derivatives
 Appl.No PCT/CN2025/099004 Applicant HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. Inventor LI, Zhen
Provided are a disaccharide compound represented by formula I, an antibody-drug conjugate containing the disaccharide compound, and the use thereof as an anti-tumor drug, etc.
10.WO/2025/252743NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
WO - 11.12.2025
Int.Class C07H 15/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
26Acyclic or carbocyclic radicals, substituted by hetero rings
 Appl.No PCT/EP2025/065359 Applicant GALECTO BIOTECH AB Inventor PETERSON, Kristoffer
The present invention relates to a high affinity galectin-3 inhibitor alpha-D-galactopyranose derivative of formula (I), a pharmaceutical salt or solvate thereof, for use in treatment of inflammation.
# -